MFN Drug Pricing Reforms Reshape Life Sciences Deal Strategy
Pharma and biotech deal teams must reassess valuations, licensing terms, and M&A structures as Medicare/Medicaid Most Favored Nation demonstration programs advance.
Federal Most Favored Nation pricing initiatives, including contemplated Medicare and Medicaid demonstration programs, are injecting material uncertainty into life sciences transactions. International reference pricing and domestic price-control mechanisms now affect asset valuations, commercialization plans, licensing and collaboration economics, and risk allocation in M&A. Counsel advising pharma and biotech clients should pressure-test diligence frameworks for pricing exposure, reprice earn-outs and milestones tied to government reimbursement, and revisit representations, indemnities, and MAC clauses. Strategic considerations include restructuring co-development and royalty arrangements, evaluating geographic launch sequencing, and preparing for shifting regulatory and reimbursement landscapes. With policy still evolving, proactive deal structuring and scenario planning are essential to mitigate downside and preserve transaction value.